Send Inquiry

Request To Call Back

Brukinsa 8 mg

Name: Brukinsa 8 mg
Brand: K. K. PHARMA SOLUTIONS
Price: 279375.0 INR
Availability: InStock

Price 279375.0 INR/ Piece

Get a Price/Quote

MOQ : 10 Pieces

Brukinsa 8 mg Specification

Salt Composition
Zanubrutinib 8 mg

Dosage Form
Capsule

Packaging Type
Bottle

Indication
Mantle cell lymphoma (MCL) in adults who have received at least one prior therapy, Waldenstroms macroglobulinemia, and other selected B-cell malignancies

Brand Name
Brukinsa

Pacakaging (Quantity Per Box)
120 capsules per bottle

Life Span
2 years from manufacturing date

Origin of Medicine
China

Drug Type
Targeted therapy/Anti-cancer

Ingredients
Zanubrutinib

Physical Form
Capsules

Function
Bruton tyrosine kinase (BTK) inhibitor for cancer treatment

Recommended For
Adults with mantle cell lymphoma (MCL) or other selected hematological malignancies

Dosage
As prescribed by physician; typically 160 mg twice daily or 320 mg once daily

Dosage Guidelines
Take orally with or without food, follow physicians instructions

Suitable For
Adults

Quantity
8 mg per capsule

Storage Instructions
Store below 30C, protect from moisture and light

Appearance
Hard gelatin capsule

Warning & Precautions
Monitor patients for bleeding, infections, cytopenias and cardiac arrhythmias

Therapeutic Class
Oncology - Hematologic Malignancies

Administration Route
Oral

Patient Information Leaflet
Included in the package

Side Effects
Neutropenia, thrombocytopenia, diarrhea, upper respiratory tract infection, hemorrhage

Contraindications
Pregnancy, hypersensitivity to Zanubrutinib

Color
White

Approval Status
US FDA Approved, NMPA China Approved

Prescription/Nonprescription
Prescription

Brukinsa 8 mg Trade Information

Minimum Order Quantity
10 Pieces

Supply Ability
500 Pieces Per Month

Delivery Time
7 Days

About Brukinsa 8 mg

Purchase Brukinsa 8 mg to experience a superb advancement in targeted oncology therapy. As a virtuoso Bruton tyrosine kinase (BTK) inhibitor, Brukinsa is valorous in treating mantle cell lymphoma (MCL) and other selected hematological malignancies in adults. Supplied in hard gelatin, white capsules, each contains 8 mg of zanubrutinib for potent, prescription-only use. Utilise this FDA and NMPA China approved offer, featuring a patient information leaflet for reference. Find certainty in its efficacy while following storage and administration guidance for optimal outcomes. For trusted, high-quality cancer management, choose Brukinsa from esteemed exporters, suppliers, and traders in India.

Indications and Applications of Brukinsa 8 mg

Brukinsa 8 mg is utilized as a frontline treatment for adults diagnosed with mantle cell lymphoma (MCL) and Waldenstrom's macroglobulinemia, especially after prior therapies. The oral administration route ensures convenience, allowing use in any setting under medical guidance. Beyond MCL, Brukinsa also demonstrates efficacy in other select B-cell malignancies, acting at the cellular level to inhibit cancer progression. This targeted therapy exemplifies a significant stride in addressing hematologic cancers.

Brukinsa 8 mg: Logistics, Availability, and Delivery

Brukinsa 8 mg is dispatched from leading FOB ports, with freight arrangements ensuring secure and prompt delivery. The packaging contains 120 capsules per bottle, safely delivered to main domestic markets across India. Boasting a robust supply ability, this product is available through verified exporters, suppliers, and traders. Customers can expect a streamlined procurement process, with efficient logistics that uphold product integrity from shipment to arrival.

FAQ's of Brukinsa 8 mg:

Q: How should Brukinsa 8 mg be administered for optimal benefit?

A: Brukinsa should be taken orally as directed by your physician, typically either 160 mg twice daily or 320 mg once daily. It can be consumed with or without food. Always adhere strictly to your doctor's dosage instructions.

Q: What is Brukinsa 8 mg primarily indicated for?

A: Brukinsa 8 mg is primarily indicated for adults with mantle cell lymphoma (MCL) who have received at least one prior therapy, as well as for Waldenstrom's macroglobulinemia and other selected B-cell malignancies.

Q: When should patients avoid using Brukinsa 8 mg?

A: Patients should avoid using Brukinsa if they are pregnant, hypersensitive to zanubrutinib, or have been advised by their healthcare provider due to specific contraindications.

Q: Where can Brukinsa 8 mg be sourced and who supplies it in India?

A: Brukinsa 8 mg is available through authorized exporters, suppliers, and traders across India. It is dispatched from major FOB ports and delivered nationwide to medical institutions and pharmacies.

Q: What precautions should patients take while using Brukinsa 8 mg?

A: Patients should be closely monitored for potential side effects such as bleeding, infections, cytopenias, and cardiac arrhythmias during the course of Brukinsa therapy. Regular consultations and lab tests are recommended to ensure safety.

Q: How does Brukinsa 8 mg work as an anti-cancer agent?

A: Brukinsa acts as a Bruton tyrosine kinase (BTK) inhibitor, effectively blocking pathways essential for cancer cell survival and proliferation, thereby offering targeted treatment for hematologic malignancies.

Tell us about your requirement